AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Feb 2022 07:00 AM
RNS
Lynparza combo delays progression risk in prostate
11 Feb 2022 03:30 PM
RNS
Director/PDMR Shareholding
10 Feb 2022 07:00 AM
RNS
AZN: Full year and Q4 2021 results
01 Feb 2022 03:00 PM
RNS
Total Voting Rights
19 Jan 2022 07:05 AM
RNS
Imfinzi improves survival in biliary tract cancer
19 Jan 2022 07:00 AM
RNS
Imfinzi combo shows unprecedented survival in HCC
17 Jan 2022 07:00 AM
RNS
Enhertu granted Priority Review for breast cancer
07 Jan 2022 07:00 AM
RNS
AstraZeneca and Neurimmune sign deal for NI006
05 Jan 2022 07:00 AM
RNS
Transfer of rights to Eklira, Duaklir completed
04 Jan 2022 03:00 PM
RNS
Total Voting Rights
29 Dec 2021 07:00 AM
RNS
AstraZeneca and Ionis close eplontersen deal
21 Dec 2021 07:00 AM
RNS
Ultomiris accepted for FDA Priority Review for gMG
20 Dec 2021 07:05 AM
RNS
Tezspire approved in the US for severe asthma
20 Dec 2021 07:00 AM
RNS
Saphnelo recommended for EU approval for SLE
15 Dec 2021 03:00 PM
RNS
Director/PDMR Shareholding
09 Dec 2021 07:00 AM
RNS
Evusheld US FDA EUA
07 Dec 2021 07:00 AM
RNS
AstraZeneca, Ionis to collaborate on eplontersen
01 Dec 2021 03:00 PM
RNS
Block listing Interim Review
01 Dec 2021 03:00 PM
RNS
Total Voting Rights
30 Nov 2021 07:00 AM
RNS
Lynparza granted FDA Priority Review for OlympiA
15 Nov 2021 04:00 PM
RNS
Director/PDMR Shareholding
12 Nov 2021 07:00 AM
RNS
AZN: Year to date and Q3 2021 results
01 Nov 2021 03:00 PM
RNS
Total Voting Rights
01 Nov 2021 07:00 AM
RNS
AstraZeneca to transfer rights to Eklira, Duaklir
25 Oct 2021 07:00 AM
RNS
Imfinzi improved survival in biliary tract cancer
18 Oct 2021 07:00 AM
RNS
AZ recommends ADS holders reject mini-tender offer
15 Oct 2021 07:00 AM
RNS
Imfinzi & tremelimumab improved OS in liver cancer
11 Oct 2021 07:00 AM
RNS
AZD7442 PhIII trial positive in COVID outpatients
04 Oct 2021 07:00 AM
RNS
Enhertu granted BTD for breast cancer
01 Oct 2021 03:00 PM
RNS
Total Voting Rights
30 Sep 2021 04:00 PM
RNS
Director/PDMR Shareholding
29 Sep 2021 07:00 AM
RNS
AstraZeneca to fully acquire Caelum Biosciences
28 Sep 2021 07:00 AM
RNS
Saphnelo approved in Japan for SLE
24 Sep 2021 07:00 AM
RNS
Lynparza PROpel trial meets primary endpoint
23 Sep 2021 07:00 AM
RNS
Board Committee Change
23 Sep 2021 07:00 AM
RNS
New Sustainability Committee of the Board
21 Sep 2021 07:00 AM
RNS
AstraZeneca $360m Irish manufacturing investment
20 Sep 2021 07:00 AM
RNS
Enhertu reduced risk of disease progression by 72%
09 Sep 2021 04:00 PM
RNS
Imfinzi improves survival in NSCLC in POSEIDON
09 Sep 2021 07:00 AM
RNS
PT027 PhIII asthma trials met primary endpoints
03 Sep 2021 07:00 AM
RNS
Ultomiris approved in EU for children with PNH
01 Sep 2021 03:00 PM
RNS
Total Voting Rights
26 Aug 2021 07:05 AM
RNS
Forxiga approved in Japan for CKD
26 Aug 2021 07:00 AM
RNS
ALXN1840 Wilson Phase III met primary endpoint
20 Aug 2021 07:05 AM
RNS
Update on Ultomiris Phase III ALS trial
20 Aug 2021 07:00 AM
RNS
AZD7442 prophylaxis trial met primary endpoint
16 Aug 2021 03:00 PM
RNS
Director/PDMR Shareholding
11 Aug 2021 02:35 PM
RNS
Update on US review of roxadustat
09 Aug 2021 07:05 AM
RNS
Forxiga approved in the EU for CKD
09 Aug 2021 07:00 AM
RNS
Enhertu head-to-head trial meets primary endpoint

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings